Introduction – Company Background

GuangXin Industrial Co., Ltd. is a specialized manufacturer dedicated to the development and production of high-quality insoles.

With a strong foundation in material science and footwear ergonomics, we serve as a trusted partner for global brands seeking reliable insole solutions that combine comfort, functionality, and design.

With years of experience in insole production and OEM/ODM services, GuangXin has successfully supported a wide range of clients across various industries—including sportswear, health & wellness, orthopedic care, and daily footwear.

From initial prototyping to mass production, we provide comprehensive support tailored to each client’s market and application needs.

At GuangXin, we are committed to quality, innovation, and sustainable development. Every insole we produce reflects our dedication to precision craftsmanship, forward-thinking design, and ESG-driven practices.

By integrating eco-friendly materials, clean production processes, and responsible sourcing, we help our partners meet both market demand and environmental goals.

Core Strengths in Insole Manufacturing

At GuangXin Industrial, our core strength lies in our deep expertise and versatility in insole and pillow manufacturing. We specialize in working with a wide range of materials, including PU (polyurethane), natural latex, and advanced graphene composites, to develop insoles and pillows that meet diverse performance, comfort, and health-support needs.

Whether it's cushioning, support, breathability, or antibacterial function, we tailor material selection to the exact requirements of each project-whether for foot wellness or ergonomic sleep products.

We provide end-to-end manufacturing capabilities under one roof—covering every stage from material sourcing and foaming, to precision molding, lamination, cutting, sewing, and strict quality control. This full-process control not only ensures product consistency and durability, but also allows for faster lead times and better customization flexibility.

With our flexible production capacity, we accommodate both small batch custom orders and high-volume mass production with equal efficiency. Whether you're a startup launching your first insole or pillow line, or a global brand scaling up to meet market demand, GuangXin is equipped to deliver reliable OEM/ODM solutions that grow with your business.

Customization & OEM/ODM Flexibility

GuangXin offers exceptional flexibility in customization and OEM/ODM services, empowering our partners to create insole products that truly align with their brand identity and target market. We develop insoles tailored to specific foot shapes, end-user needs, and regional market preferences, ensuring optimal fit and functionality.

Our team supports comprehensive branding solutions, including logo printing, custom packaging, and product integration support for marketing campaigns. Whether you're launching a new product line or upgrading an existing one, we help your vision come to life with attention to detail and consistent brand presentation.

With fast prototyping services and efficient lead times, GuangXin helps reduce your time-to-market and respond quickly to evolving trends or seasonal demands. From concept to final production, we offer agile support that keeps you ahead of the competition.

Quality Assurance & Certifications

Quality is at the heart of everything we do. GuangXin implements a rigorous quality control system at every stage of production—ensuring that each insole meets the highest standards of consistency, comfort, and durability.

We provide a variety of in-house and third-party testing options, including antibacterial performance, odor control, durability testing, and eco-safety verification, to meet the specific needs of our clients and markets.

Our products are fully compliant with international safety and environmental standards, such as REACH, RoHS, and other applicable export regulations. This ensures seamless entry into global markets while supporting your ESG and product safety commitments.

ESG-Oriented Sustainable Production

At GuangXin Industrial, we are committed to integrating ESG (Environmental, Social, and Governance) values into every step of our manufacturing process. We actively pursue eco-conscious practices by utilizing eco-friendly materials and adopting low-carbon production methods to reduce environmental impact.

To support circular economy goals, we offer recycled and upcycled material options, including innovative applications such as recycled glass and repurposed LCD panel glass. These materials are processed using advanced techniques to retain performance while reducing waste—contributing to a more sustainable supply chain.

We also work closely with our partners to support their ESG compliance and sustainability reporting needs, providing documentation, traceability, and material data upon request. Whether you're aiming to meet corporate sustainability targets or align with global green regulations, GuangXin is your trusted manufacturing ally in building a better, greener future.

Let’s Build Your Next Insole Success Together

Looking for a reliable insole manufacturing partner that understands customization, quality, and flexibility? GuangXin Industrial Co., Ltd. specializes in high-performance insole production, offering tailored solutions for brands across the globe. Whether you're launching a new insole collection or expanding your existing product line, we provide OEM/ODM services built around your unique design and performance goals.

From small-batch custom orders to full-scale mass production, our flexible insole manufacturing capabilities adapt to your business needs. With expertise in PU, latex, and graphene insole materials, we turn ideas into functional, comfortable, and market-ready insoles that deliver value.

Contact us today to discuss your next insole project. Let GuangXin help you create custom insoles that stand out, perform better, and reflect your brand’s commitment to comfort, quality, and sustainability.

🔗 Learn more or get in touch:
🌐 Website: https://www.deryou-tw.com/
📧 Email: shela.a9119@msa.hinet.net
📘 Facebook: facebook.com/deryou.tw
📷 Instagram: instagram.com/deryou.tw

Soft-touch pillow OEM service in Taiwan

Are you looking for a trusted and experienced manufacturing partner that can bring your comfort-focused product ideas to life? GuangXin Industrial Co., Ltd. is your ideal OEM/ODM supplier, specializing in insole production, pillow manufacturing, and advanced graphene product design.

With decades of experience in insole OEM/ODM, we provide full-service manufacturing—from PU and latex to cutting-edge graphene-infused insoles—customized to meet your performance, support, and breathability requirements. Our production process is vertically integrated, covering everything from material sourcing and foaming to molding, cutting, and strict quality control.Private label insole and pillow OEM Vietnam

Beyond insoles, GuangXin also offers pillow OEM/ODM services with a focus on ergonomic comfort and functional innovation. Whether you need memory foam, latex, or smart material integration for neck and sleep support, we deliver tailor-made solutions that reflect your brand’s values.

We are especially proud to lead the way in ESG-driven insole development. Through the use of recycled materials—such as repurposed LCD glass—and low-carbon production processes, we help our partners meet sustainability goals without compromising product quality. Our ESG insole solutions are designed not only for comfort but also for compliance with global environmental standards.High-performance insole OEM factory Taiwan

At GuangXin, we don’t just manufacture products—we create long-term value for your brand. Whether you're developing your first product line or scaling up globally, our flexible production capabilities and collaborative approach will help you go further, faster.Taiwan athletic insole OEM supplier

📩 Contact us today to learn how our insole OEM, pillow ODM, and graphene product design services can elevate your product offering—while aligning with the sustainability expectations of modern consumers.Soft-touch pillow OEM service in Vietnam

Implanted electrodes stream recorded data to a pocket-sized device worn by a patient. The data are then wirelessly transferred to a tablet and then uploaded to the cloud via a HIPAA-compliant server. Credit: Image courtesy of Starr lab, UCSF NIH BRAIN Initiative-funded study opens the door to correlating deep brain activity and behavior. Researchers are now able to wirelessly record the directly measured brain activity of patients living with Parkinson’s disease and to then use that information to adjust the stimulation delivered by an implanted device. Direct recording of deep and surface brain activity offers a unique look into the underlying causes of many brain disorders; however, technological challenges up to this point have limited direct human brain recordings to relatively short periods of time in controlled clinical settings. This project, published in the journal Nature Biotechnology, was funded by the National Institutes of Health’s Brain Research Through Advancing Innovative Neurotechnologies (BRAIN) Initiative. “This is really the first example of wirelessly recording deep and surface human brain activity for an extended period of time in the participants’ home environment,” said Kari Ashmont, Ph.D., project manager for the NIH BRAIN Initiative. “It is also the first demonstration of adaptive deep brain stimulation at home.” Deep brain stimulation (DBS) devices are approved by the U. S. Food and Drug Administration for the management of Parkinson’s disease symptoms by implanting a thin wire, or electrode, that sends electrical signals into the brain. In 2018, the laboratory of Philip Starr, M.D., Ph.D. at the University of California, San Francisco, developed an adaptive version of DBS that adapts its stimulation only when needed based on recorded brain activity. In this study, Dr. Starr and his colleagues made several additional improvements to the implanted technology. “This is the first device that allows for continuous and direct wireless recording of the entire brain signal over many hours,” said Dr. Starr. “That means we are able to perform whole brain recording over a long period of time while people are going about their daily lives.” The implications of this type of recording are significant. The brain activity patterns (neural signatures) normally used to identify problems such as Parkinson’s disease symptoms have traditionally been recorded in clinical settings over short periods of time. This new technology makes it possible to validate those signatures during ordinary daily activities. “If you ever hope to use in-hospital recordings to modify a disease state through adaptive stimulation, you must show that they are also valid in the real world,” said Dr. Starr. Another advantage to recording over long periods of time is that distinct changes in brain activity (biomarkers) that could predict movement disorders can now be identified for individual patients. Ro’ee Gilron, Ph.D., a postdoctoral scholar in Dr. Starr’s lab and first author of this study, explained that this allows for a level of customized DBS treatment that was impossible to achieve previously. “Because we are able to build a biomarker library for each patient, we can now program each DBS unit according to a patient’s individual needs,” said Dr. Gilron. “This includes personalized stimulation programs that adapt as the patient’s needs change throughout the day.” One important consideration that arises is the ethical implication of (nearly) all-day brain recording. Since its beginning, the NIH BRAIN Initiative has recognized the importance of addressing potential ethical considerations pertaining to the development and use of devices that record or modulate brain activity. For instance, the NIH BRAIN Neuroethics Working Group is a group of experts in neuroethics and neuroscience that serves to provide the NIH BRAIN Initiative with input relating to neuroethics — a field that studies the ethical, legal, and societal implications of neuroscience. Alongside funding for neurotechnology research, the Initiative also funds research on the ethical implications of advancements in neurotechnology. “We have had patients approach us with concerns regarding privacy,” said Dr. Starr. “Although we are not at the point where we can distinguish specific normal behaviors from brain activity recording, it is an absolutely legitimate concern. We have told patients to feel free to remove their wearable devices and to turn off their brain recordings whenever they engage in activities they would like to keep private.” The patients were also invited to participate in NIH BRAIN Initiative-funded neuroethics projects looking to identify concerns about this new technology (MH114860). In addition, individuals who opted out of the implant project were interviewed about their decision. As recommended by a recent BRAIN 2.0 neuroethics report, this information will be used to develop ethical guidelines and protocols for future projects to achieve a healthy balance between discovery and privacy. One unforeseen benefit of this study was that, because it required little to no direct contact with clinicians following surgery, it was ideally suited for the social distancing that is crucial during the COVID-19 pandemic. The technologies used for remote patient monitoring and telehealth were originally designed for the convenience of study subjects, but they have broader applications to other research projects that have been stalled due to COVID-19. “The technologies we developed and used to communicate and work remotely with our patients can also allow those who do not live close to a clinic to receive ‘over the air’ updates for their devices and telehealth visits from their neurologists as they manage increasingly complex DBS devices,” said Dr. Gilron. The importance of studying behavior in a natural environment such as the home as it relates to neural activity was emphasized in a recent BRAIN 2.0 neuroscience report. Dr. Ashmont stressed that this study is a significant step in that direction and is going to help scientists understand not only disorders but also the neural representation of behaviors in general. Reference: “Long-term wireless streaming of neural recordings for circuit discovery and adaptive stimulation in individuals with Parkinson’s disease” by Ro’ee Gilron, Simon Little, Randy Perrone, Robert Wilt, Coralie de Hemptinne, Maria S. Yaroshinsky, Caroline A. Racine, Sarah S. Wang, Jill L. Ostrem, Paul S. Larson, Doris D. Wang, Nick B. Galifianakis, Ian O. Bledsoe, Marta San Luciano, Heather E. Dawes, Gregory A. Worrell, Vaclav Kremen, David A. Borton, Timothy Denison and Philip A. Starr, 3 May 2021, Nature Biotechnology. DOI: 10.1038/s41587-021-00897-5 This research was funded by a grant from the NIH BRAIN Initiative (NS100544).

Scientists have created SMART, a software for simulating complex cell-signaling networks, enhancing research in pharmacology, systems biology, and more. Credit: UCSD Researchers at UC San Diego have developed SMART, a software package capable of realistically simulating cell-signaling networks. This tool, tested across various biological systems, enhances the understanding of cellular responses and aids in advancing research in fields like systems biology and pharmacology. Researchers at the University of California San Diego (UCSD) have developed and tested a new software tool called Spatial Modeling Algorithms for Reactions and Transport (SMART). This innovative software can accurately simulate cell-signaling networks — the intricate systems of molecular interactions that enable cells to respond to signals from their environment. These networks are complex due to the many steps involved and the three-dimensional shapes of cells and their components, making them challenging to model with existing tools. SMART addresses these challenges, promising to accelerate research in fields such as systems biology, pharmacology, and biomedical engineering. The team successfully tested SMART across various biological systems, including cell responses to adhesive signals, calcium release in neurons and heart muscle cells, and ATP production within a detailed mitochondrial model. With its flexible, precise, and efficient simulation capabilities, SMART opens new possibilities for understanding cellular behavior and developing treatments for human diseases. This video shows a simulation created with SMART that showcases the calcium release dynamics within heart cells. This process is essential for heart muscles to contract. The researchers successfully tested the new software in biological systems at several different scales, from cell signaling in response to adhesive cues, to calcium release events in subcellular regions of neurons and cardiac muscle cells, to the production of ATP (the energy currency in cells) within a detailed representation of a single mitochondrion. By providing a flexible, accurate and efficient tool for modeling cell-signaling networks, SMART paves the way for more detailed simulations to advance our understanding of cellular behavior and drive the development of new treatments for human diseases. The study, published today (December 19) in Nature Computational Science, was led by Emmet Francis, Ph.D., an American Society for Engineering Education postdoctoral fellow in the research group supervised by Professor Padmini Rangamani, Ph.D., both affiliated with the Department of Pharmacology at UC San Diego School of Medicine and the Department of Mechanical and Aerospace Engineering at UC San Diego Jacobs School of Engineering. The initial version of this software was written by Justin Laughlin, Ph.D., a former graduate student in Rangamani’s group. Reference: “Spatial modeling algorithms for reactions and transport in biological cells” by Emmet A. Francis, Justin G. Laughlin, Jørgen S. Dokken, Henrik N. T. Finsberg, Christopher T. Lee, Marie E. Rognes and Padmini Rangamani, 19 December 2024, Nature Computational Science. DOI: 10.1038/s43588-024-00745-x SMART is part of an ongoing collaboration with a research team led by Marie Rognes, Ph.D., at Simula Research Laboratory in Oslo, Norway. This research was funded, in part, by the National Science Foundation, the Wu Tsai Human Performance Alliance, the Air Force Office of Scientific Research, the Hartwell Foundation, the Kavli Institute of Brain and Mind, the European Research Council, the Research Council of Norway, the K. G. Jebsen Center for Brain Fluid Research, and the Fulbright Foundation.

Researchers in Wyoming have discovered that cyclotides from violets, particularly kalata B1, can boost the potency of TMZ chemotherapy in treating glioblastoma, offering potential for improved treatment options. Synthetic versions of kalata B1 are now being produced for further testing. Violets’ cyclotides could revolutionize glioblastoma treatment by boosting chemotherapy efficacy, now advancing to mouse model testing. Glioblastoma is one of the deadliest brain diseases known. More than 45% of brain cancers are gliomas. Only half of glioblastoma patients respond to the FDA-approved chemotherapy Temozolomide (TMZ). Even for those patients, the cancer cells quickly evolve resistance. The majority of patients pass away within 12 to 16 months after diagnosis, and few make it beyond five years. However, a glimmer of hope for patients is emerging from an unexpected source: Jackson Hole, Wyoming, where scientists at the non-profit Brain Chemistry Labs have been researching molecules found in violets. Wyoming violets. Credit: Dr. Paul Alan Cox, Brain Chemistry Labs Cyclotides: Nature’s Cancer Fighters Violets produce a dazzling suite of small circular peptides called cyclotides. They roughly appear in shape “like floppy frisbees,” says Dr. Samantha L. Gerlach. “They have been found active in the test tube against certain types of human cancer cells.” Disulfide crosslinks which maintain the shape of cyclotides may help them create pores in the membranes of cancer cells. Within the plant, cyclotides provide protection against insect herbivores, fungal infections, and viruses. Cyclotides were originally discovered from an herbal tea used by indigenous people in Africa to ease the course of childbirth. The tea was made from a plant they call kalata-kalata, which scientists call Oldenlandia affinis. Violet researcher Dr. Samantha Gerlach at Brain Chemistry Labs. Credit: Dr. Paul Alan Cox, Brain Chemistry Labs Breakthrough with Cyclotide Kalata B1 In a new study published in Biomedicines, an international team led by scientists in Jackson Hole announced that the cyclotide kalata B1 turbocharges the activity of the chemotherapy TMZ, decreasing the amount necessary to kill glioblastoma cells by over ten-fold. Senior author Dr. Gerlach and her colleagues demonstrated that a synthetic version of kalata B1 has equal efficacy to the natural molecule. “While kalata B1 commonly occurs in violet species, extraction from plant material yields only minuscule amounts,” Gerlach states. “Working day and night for months, the minimal quantities we obtain are insufficient for clinical research.” Synthetic Production and Future Research Through a collaboration with CSBio in California, the scientists were able to obtain much larger quantities of the synthetic version that were sufficient for testing in mouse models of glioblastoma. The structure and efficacy of synthetic kalata B1 were found to be equivalent in all respects to the naturally occurring molecule. Dr. Krish Krishnan at California State University, Fresno used Nuclear Magnetic Resonance (NMR) spectroscopy to confirm the shape and folding of the synthetic molecule. “Our cell data suggest that we can now move forward with the synthetic version in mice models,” Dr. Rachael Dunlop at the Brain Chemistry Labs stated. This next step of testing in mice will occur in Vienna, Austria. While Brain Chemistry Labs Director Dr. Paul Alan Cox believes that the advent of synthetic kalata B1 could be a major step forward, he is cautious about overstating the significance for patients. “We are still a long ways from clinical trials, but now the way is clear to determine if it might be safe for further testing.” Reference: “Kalata B1 Enhances Temozolomide Toxicity to Glioblastoma Cells” by Samantha L. Gerlach, James S. Metcalf, Rachael A. Dunlop, Sandra Anne Banack, Cheenou Her, Viswanathan V. Krishnan, Ulf Göransson, Sunithi Gunasekera, Blazej Slazak and Paul Alan Cox, 27 September 2024, Biomedicines. DOI: 10.3390/biomedicines12102216

DVDV1551RTWW78V